JPWO2020047447A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047447A5 JPWO2020047447A5 JP2021511547A JP2021511547A JPWO2020047447A5 JP WO2020047447 A5 JPWO2020047447 A5 JP WO2020047447A5 JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021511547 A JP2021511547 A JP 2021511547A JP WO2020047447 A5 JPWO2020047447 A5 JP WO2020047447A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 120
- 150000003839 salts Chemical class 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 208000019622 heart disease Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000001475 halogen functional group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 12
- 230000002861 ventricular Effects 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 9
- 210000002235 sarcomere Anatomy 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- -1 3-oxetanyl Chemical group 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 208000011518 Danon disease Diseases 0.000 claims description 6
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 6
- 208000024720 Fabry Disease Diseases 0.000 claims description 6
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims description 6
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 206010029748 Noonan syndrome Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000002107 myocardial effect Effects 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 230000000414 obstructive effect Effects 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical class C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 206010027727 Mitral valve incompetence Diseases 0.000 claims description 3
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 206010039163 Right ventricular failure Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 206010002906 aortic stenosis Diseases 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000028831 congenital heart disease Diseases 0.000 claims description 3
- 208000028208 end stage renal disease Diseases 0.000 claims description 3
- 201000000523 end stage renal failure Diseases 0.000 claims description 3
- 208000007345 glycogen storage disease Diseases 0.000 claims description 3
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 238000007634 remodeling Methods 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024028682A JP2024054409A (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726162P | 2018-08-31 | 2018-08-31 | |
| US62/726,162 | 2018-08-31 | ||
| PCT/US2019/049118 WO2020047447A1 (en) | 2018-08-31 | 2019-08-30 | Cardiac sarcomere inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028682A Division JP2024054409A (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535164A JP2021535164A (ja) | 2021-12-16 |
| JPWO2020047447A5 true JPWO2020047447A5 (enExample) | 2022-10-18 |
| JP7447089B2 JP7447089B2 (ja) | 2024-03-11 |
Family
ID=67953902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511547A Active JP7447089B2 (ja) | 2018-08-31 | 2019-08-30 | 心筋サルコメア阻害剤 |
| JP2024028682A Pending JP2024054409A (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028682A Pending JP2024054409A (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11414424B2 (enExample) |
| EP (1) | EP3843842A1 (enExample) |
| JP (2) | JP7447089B2 (enExample) |
| KR (1) | KR20210068422A (enExample) |
| CN (2) | CN118955409A (enExample) |
| AR (1) | AR116283A1 (enExample) |
| AU (1) | AU2019328556B2 (enExample) |
| BR (1) | BR112021003496A2 (enExample) |
| CA (1) | CA3110237A1 (enExample) |
| CL (1) | CL2021000481A1 (enExample) |
| CO (1) | CO2021003115A2 (enExample) |
| EA (1) | EA202190657A1 (enExample) |
| EC (1) | ECSP21016009A (enExample) |
| IL (2) | IL315709A (enExample) |
| MA (1) | MA53491A (enExample) |
| MX (1) | MX2021002199A (enExample) |
| PH (1) | PH12021550400A1 (enExample) |
| SG (1) | SG11202101769YA (enExample) |
| TW (1) | TWI848972B (enExample) |
| UY (1) | UY38358A (enExample) |
| WO (1) | WO2020047447A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117924208A (zh) | 2018-01-19 | 2024-04-26 | 赛特凯恩蒂克公司 | 作为心肌节抑制剂的二氢苯并呋喃和茚类似物 |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| AU2019328556B2 (en) | 2018-08-31 | 2025-09-04 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
| US20240246901A1 (en) * | 2020-03-11 | 2024-07-25 | Sheldon Cao | Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases |
| IL300775A (en) | 2020-08-28 | 2023-04-01 | Myokardia Inc | Treatment methods with myosin modulator |
| US20230373972A1 (en) * | 2020-09-17 | 2023-11-23 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Piperazine derivative, preparation method therefor and use thereof |
| JP2023550444A (ja) * | 2020-11-20 | 2023-12-01 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 |
| WO2022187501A1 (en) | 2021-03-04 | 2022-09-09 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US20250288586A1 (en) | 2022-04-26 | 2025-09-18 | MyoKardia, Inc. | Methods of Administering Myosin Inhibitors |
| US20240132498A1 (en) | 2022-09-02 | 2024-04-25 | Cytokinetics, Incorporated | Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) * | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1999038149A1 (en) | 1998-01-26 | 1999-07-29 | Wayne Westerman | Method and apparatus for integrating manual input |
| AU2002365057A1 (en) * | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| WO2004064730A2 (en) | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1621540A4 (en) * | 2003-04-21 | 2008-07-23 | Ono Pharmaceutical Co | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF |
| AU2005264988B2 (en) | 2004-06-17 | 2011-09-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| MX2007006230A (es) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) * | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| SI3247707T1 (sl) | 2015-01-22 | 2023-10-30 | MyoKardia, Inc. | S 4-metilsulfonilom substituirane spojine piperidina sečnine, uporabne za zdravljenje srčnih motenj, kot je dilatacijska kardiomiopatija (dcm) |
| BR112018012390B1 (pt) | 2015-12-17 | 2023-03-14 | Syngenta Participations Ag | Derivados de oxadiazol microbiocidas |
| US20190364899A1 (en) | 2015-12-18 | 2019-12-05 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| WO2018089433A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| CN117924208A (zh) | 2018-01-19 | 2024-04-26 | 赛特凯恩蒂克公司 | 作为心肌节抑制剂的二氢苯并呋喃和茚类似物 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| AU2019328556B2 (en) | 2018-08-31 | 2025-09-04 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
| MX2022000504A (es) | 2019-07-17 | 2022-02-10 | Cytokinetics Inc | Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida. |
| KR20220082804A (ko) | 2019-07-17 | 2022-06-17 | 싸이토키네틱스, 인코포레이티드 | 심장 근섬유분절 억제제 경구 제제들 |
| TW202134259A (zh) | 2019-11-10 | 2021-09-16 | 美商邁奧卡迪亞公司 | 用肌凝蛋白調節劑之治療方法 |
| IL300775A (en) | 2020-08-28 | 2023-04-01 | Myokardia Inc | Treatment methods with myosin modulator |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| JP2023550444A (ja) | 2020-11-20 | 2023-12-01 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| WO2022187501A1 (en) | 2021-03-04 | 2022-09-09 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US20240132498A1 (en) | 2022-09-02 | 2024-04-25 | Cytokinetics, Incorporated | Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde |
-
2019
- 2019-08-30 AU AU2019328556A patent/AU2019328556B2/en active Active
- 2019-08-30 MA MA053491A patent/MA53491A/fr unknown
- 2019-08-30 CA CA3110237A patent/CA3110237A1/en active Pending
- 2019-08-30 CN CN202410976837.3A patent/CN118955409A/zh active Pending
- 2019-08-30 UY UY0001038358A patent/UY38358A/es active IP Right Grant
- 2019-08-30 CN CN201980068999.4A patent/CN112867539B/zh active Active
- 2019-08-30 IL IL315709A patent/IL315709A/en unknown
- 2019-08-30 EP EP19768990.4A patent/EP3843842A1/en active Pending
- 2019-08-30 TW TW108131375A patent/TWI848972B/zh active
- 2019-08-30 US US16/557,281 patent/US11414424B2/en active Active
- 2019-08-30 IL IL281075A patent/IL281075B2/en unknown
- 2019-08-30 AR ARP190102477A patent/AR116283A1/es unknown
- 2019-08-30 MX MX2021002199A patent/MX2021002199A/es unknown
- 2019-08-30 SG SG11202101769YA patent/SG11202101769YA/en unknown
- 2019-08-30 WO PCT/US2019/049118 patent/WO2020047447A1/en not_active Ceased
- 2019-08-30 KR KR1020217008799A patent/KR20210068422A/ko active Pending
- 2019-08-30 EA EA202190657A patent/EA202190657A1/ru unknown
- 2019-08-30 JP JP2021511547A patent/JP7447089B2/ja active Active
- 2019-08-30 BR BR112021003496-0A patent/BR112021003496A2/pt unknown
-
2021
- 2021-02-25 CL CL2021000481A patent/CL2021000481A1/es unknown
- 2021-02-26 PH PH12021550400A patent/PH12021550400A1/en unknown
- 2021-03-09 EC ECSENADI202116009A patent/ECSP21016009A/es unknown
- 2021-03-10 CO CONC2021/0003115A patent/CO2021003115A2/es unknown
-
2022
- 2022-05-04 US US17/736,895 patent/US11952381B2/en active Active
-
2024
- 2024-02-26 US US18/587,730 patent/US12275741B2/en active Active
- 2024-02-28 JP JP2024028682A patent/JP2024054409A/ja active Pending
-
2025
- 2025-01-08 US US19/014,118 patent/US20250276976A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020047447A5 (enExample) | ||
| JP2021516240A5 (enExample) | ||
| US5599826A (en) | Thiazolidinediones and drugs containing them | |
| JPWO2019144041A5 (enExample) | ||
| RU2004105956A (ru) | Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. | |
| NZ542072A (en) | Compounds for the treatment of metabolic disorders | |
| JP2007504284A5 (enExample) | ||
| JP2007511563A (ja) | 新規チアゾリジン−４−オン誘導体 | |
| JP2004534035A5 (enExample) | ||
| RU2003112610A (ru) | Производные пиразола для лечения вирксных заболеваний | |
| JP2005534672A5 (enExample) | ||
| NO327709B1 (no) | 2'-substituerte 1,1'-bifenyl-2-karbonamider, deres anvendelse for fremstilling av et medikament sa vel som farmasoytiske preparater inneholdende disse | |
| RU2014107000A (ru) | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств | |
| JP2020111571A5 (enExample) | ||
| JP4285723B2 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| JP2004532862A (ja) | 線維性疾患又は他の適応症の治療方法 | |
| JP2007531764A5 (enExample) | ||
| JPWO2020005888A5 (enExample) | ||
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| EP0222358B1 (en) | Cardiotonic heterocyclic oxazolones | |
| JP4774995B2 (ja) | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 | |
| US4670450A (en) | Cardiotonic thiazolones | |
| JPWO2022187501A5 (enExample) | ||
| IE48946B1 (en) | Substituted furans | |
| CA2108064C (fr) | Nouveaux composes de thiazolidine dione, leur procede de preparation et les compositions pharmaceutiques les contenant |